# Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

> clinical trial · VERIFIED · 2026-08-13

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Anaplastic Large Cell Lymphoma, ALK-Negative

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT02978625

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.